Infliximab como tratamiento de la enfermedad de Crohn en un paciente con inmunodeficiencia común variable

Common variable immunodeficiency (CVID) and Crohn's disease (CD) can coexist and this may hinder the diagnosis and management of CD.

We report the case of a 58 year old woman with a history of CVID, who was diagnosed with CD 24 years ago. Initially she received corticosteroids, but developed corticodependence, so azatioprinais initiated. Nevertheless, she suffered new flares and perianal disease, so it was decided to initiate biological treatment (infliximab). Currently, she has received induction and three maintenance doses, with favourable evolution of her CD, and without incidents regarding her previous immunodeficiency.

We wish to emphasize that infliximab is safe in patients with such immunodeficiency; in published cases, as in ours, there have not been adverse events, although a tight control should be kept on such patients, due to the increase in the risk of developing infections or malignancies.